Company Overview
Company Type: Public Company
Website: www.sironabiochem.com
Number of Employees: -
Ticker: SBM (TSXV)
Year Founded: 2006


Business Description
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.1
Market Capitalization
24.0
TEV/Total Revenue
300.0x
EBITDA
(2.1)
Total Enterprise Value
25.3
TEV/EBITDA
NM
EBIT
(2.1)
Cash & ST Invst.
0.3
P/Diluted EPS Before Extra
NM
Net Income
(2.3)
Total Debt
1.7
Price/Tang BV
NM
Total Assets
1.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Verrico, Howard J.
Founder, Chairman of the Board, CEO & Secretary
Hopton, Christopher D.
CFO & Director
Deliencourt-Godefroy, Géraldine 
Chief Scientific Officer & Director

Key Board Members
Name
Title
Verrico, Howard J.
Founder, Chairman of the Board, CEO & Secretary
Hopton, Christopher D.
CFO & Director
Deliencourt-Godefroy, Géraldine 
Chief Scientific Officer & Director
Bieber, Wolfgang 
Member of Strategic Advisory Board
Du, Caigan 
Member of Strategic Advisory Board
Marazzi, Alex Sandro
Independent Director
Richard, Denis 
Member of Strategic Advisory Board
Tian, Jason 
Independent Director
Verchere, Bruce 
Member of Strategic Advisory Board
Walker, Michael J. A.
Member of Strategic Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
595 Burrard Street | Vancouver, BC | V7X 1L4 | Canada

Current and Pending Investors
AlphaNorth Asset Management, Moody Capital Solutions, Inc., Pathfinder Asset Management Limited, Wanbang Biopharmaceuticals Co., Ltd. (Pending)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.10
Market Cap (mm)
24.0
Open
 0.10
Shares Out. (mm)
252.2
Previous Close
 0.10
Float %
96.0%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(9.5)%
Dividend Yield %
-
Day High/Low
 0.10/ 0.10
Diluted EPS Excl. Extra Items
(0.01)
52 wk High/Low
 0.22/ 0.08
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0016
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
(0.23)


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
TSXV:SBM - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
TFChem S.A.S.
TFChem S.A.S., a drug-discovery company, develops and markets fluorinated glycomimetic compounds for pharmaceutical and biotechnological companies. The company’s portfolio includes analogs of existing glycoconjugates, neo-glycosylation of active molecules, and new chemical entities fluoroglycosylated. Its chemistry technology is applied to the development of various pharmaceutical domains, such as cancer, diabetes, pain and inflammation, and cardio-vascular diseases, as well as to develop cosmetic and biological ingredients. The company was incorporated in 2009 and is based in Val-de-Reuil, France. TFChem S.A.S. operates as a subsidiary of Sirona Biochem Corp.

Europe
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-23-2023
Apr-20-2023
Private Placement
Target
Sirona Biochem Corp. (TSXV:SBM)


1.16
Jul-09-2019
Jul-10-2019
Private Placement
Target
Sirona Biochem Corp. (TSXV:SBM)


1.14
Feb-15-2019
Feb-27-2019
Private Placement
Target
Sirona Biochem Corp. (TSXV:SBM)


1.36
Oct-16-2018
Oct-16-2018
Private Placement
Target
Sirona Biochem Corp. (TSXV:SBM)


0.55
Oct-24-2017
Oct-26-2017
Private Placement
Target
Sirona Biochem Corp. (TSXV:SBM)


0.49
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-28-2023
Product-Related Announcements
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEB
Jun-06-2023
Company Conference Presentations
Sirona Biochem Corp. Presents at BIO International Convention 2023, Jun-06-2023 10:00 AM
Apr-25-2023
Product-Related Announcements
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326
Apr-20-2023
Private Placements
Sirona Biochem Corp. announced that it has received CAD 1.563 million in funding
Mar-23-2023
Private Placements
Sirona Biochem Corp. announced that it expects to receive CAD 1.5 million in funding

M&A Advisors
Boughton Law Corporation


Advisors
Most Recent Auditor
DeVisser Gray LLP
M&A Advisors
Boughton Law Corporation
Public Offering Advisors
Amisano Hanson, DLA Piper (Canada) LLP


Most Recent Auditor
De Visser Gray


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:47 AM
SBM
Sirona Biochem Corp 2023_10_05
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 19, 2023 06:00 PM
SBM
Rating Update for Sirona Biochem Corp
EPS Estimates*
3
GlobalData

Sep 15, 2023 07:30 AM
SBM
Sirona Biochem Corp (SBM.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
42
MarketLine

Sep 14, 2023 06:01 AM
SBM
Sirona Biochem Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
114
GlobalData

Sep 11, 2023 03:36 AM
SBM
Sirona Biochem Corp (SBM.CVE) - Financial Analysis Review
Reports
149
S&P Global Compustat

Sep 07, 2023 04:45 AM
SBM
Sirona Biochem Corp 2023_09_07
Reports
14
GlobalData

Aug 23, 2023 06:43 AM
SBM
Sirona Biochem Corp (SBM.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
50
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 20, 2023 06:00 PM
SBM
Rating Update for Sirona Biochem Corp
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 31, 2023 06:00 PM
SBM
Rating Update for Sirona Biochem Corp
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 03:15 AM
SBM
Sirona Biochem Corp 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Verrico M.D., Ph.D., Howard J.

8,961,251

3.55

0.9

Jan-19-2022


Hopton C.G.A., CPA, Christopher D.

1,228,525

0.49

0.1

Jan-19-2022



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Cosmetic and Pharmaceutical Active ingredients, Licensing of TFC-039, SBM-TFC-039 (Future), SBM-TFC-1067, SBM-TFC-1165 (Future), SBM-TFC-1287 (Future), SGLT2 inhibitor, Sodium Glucose Co-transporter Inhibitors (Future), TFC-039, TFC-1067 (Future), TFC-1326 (Future), TFC-723 (Future), TFC-837 (Future), Unique SGLT


Upcoming Events
Date/Time
Type
Feb-28-2024
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
Jul-31-2023
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
Interim Financial Statements
523 KB
Jul-20-2023
Apr-30-2023
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
Interim Financial Statements
515 KB
Jul-13-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
28 KB
Jun-29-2023
Apr-30-2023
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
Interim Financial Statements
522 KB
Jun-28-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
23 KB
May-25-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
25 KB
May-11-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
19 KB
May-03-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
25 KB
Apr-27-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
Material Change Report
132 KB
Apr-25-2023
-
Sirona Biochem Corp. (TSXV:SBM)
SEDAR
News Releases
220 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Verrico M.D., Ph.D., Howard J. (Founder, Chairman of the Board, CEO & Secretary)
Jan-19-2022
Common Shares
500,000
0
Derivative Exercise and Retained Stock
5.91
Multiple
Hopton C.G.A., CPA, Christopher D. (CFO & Director)
Jan-19-2022
Common Shares
250,000
0
Derivative Exercise and Retained Stock
25.55
Multiple
Verrico M.D., Ph.D., Howard J. (Founder, Chairman of the Board, CEO & Secretary)
Oct-05-2021
Common Shares
10,000
-
Open Market Acquisition
0.12
Multiple
Verrico M.D., Ph.D., Howard J. (Founder, Chairman of the Board, CEO & Secretary)
Oct-01-2021
Common Shares
100,000
-
Open Market Acquisition
1.20
Multiple
Hopton C.G.A., CPA, Christopher D. (CFO & Director)
May-06-2021
Common Shares
20,000
-
Open Market Acquisition
2.09
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Verrico, Howard J.
Founder, Chairman of the Board, CEO & Secretary
-
-
hverrico@sironabiochem.com
Hopton, Christopher D.
CFO & Director
-
-
chris.hopton@riosilverinc.com
Deliencourt-Godefroy, Géraldine 
Chief Scientific Officer & Director
-
-

Bieber, Wolfgang 
Member of Strategic Advisory Board
-
-

Du, Caigan 
Member of Strategic Advisory Board
-
-

Marazzi, Alex Sandro
Independent Director
-
-

Richard, Denis 
Member of Strategic Advisory Board
-
-

Tian, Jason 
Independent Director
-
-

Verchere, Bruce 
Member of Strategic Advisory Board
-
-

Walker, Michael J. A.
Member of Strategic Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Verrico, Howard J.
Founder, Chairman of the Board, CEO & Secretary
-
-
hverrico@sironabiochem.com
Hopton, Christopher D.
CFO & Director
-
-
chris.hopton@riosilverinc.com
Deliencourt-Godefroy, Géraldine 
Chief Scientific Officer & Director
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
